Stealth BioTherapeutics Announces Results in Ocuvia Diabetic Macular Edema Study: The ReVIEW Trial

Promising data highlighted during Mitochondrial Science and Medicine Series
BOSTON–(BUSINESS WIRE)–Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced results from its ReVIEW study of Ocuvia in diabetic macular edema (DME) patients. The results were presented in New York City at Stealth’s second Mitochondrial Science and Medicine Series symposium focused on mitochondria’s role in ophthalmology.

“ReVIEW’s results are encouraging and demonstrate the importance of mitochondria in debilitating diseases of the eye”

ReVIEW, a clinical study of DME patients, evaluated the safety, tolerability and efficacy of Ocuvia, an investigational drug targeting mitochondrial dysfunction to treat common and rare diseases. Retinal vessel leakage and accumulation of macular fluid cause DME, leading to blurry or washed-out vision and often blindness. To date, standard care for macular diseases has been limited primarily to inhibiting angiogenesis with anti-VEGF therapies, rather than modifying disease progression by treating the underlying mitochondrial dysfunction.
ReVIEW evaluated 15 DME patients receiving Ocuvia as a monotherapy for 28 days. Patients were randomized to 0.3- and 1%- topical Ocuvia drops in ascending-dose cohorts. Ocuvia met its primary safety and tolerability endpoints including no significant decreases in visual acuity during treatment. Ocuvia also reduced central subfield thickness by 32 and 27% in both a 0.3- and 1%- treated patient, respectively, without a change in the untreated eye.
“Although ReVIEW was a safety and tolerability study, a reduction of macular edema in these patients demonstrates Ocuvia’s potential,” said Dr. Jeffrey Heier, a leading retinal specialist. “Ocuvia holds promise for patients to complement and improve retinal care,” added Dr. Heier. “Ocuvia may be the new paradigm for ophthalmology, reversing disease rather than just slowing angiogenesis,” commented Dr. Pravin Dugel, Chairman for the American Academy of Ophthalmology Subspecialty Day, when describing Ocuvia’s clinical benefits and the role of mitochondria in eye diseases……….
Read more:
Source: BusinessWire